Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05703971 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Name: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients — clinical trial record (NCT05703971)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Acclaim-3

StatusRecruiting

PhasePhase 1/2

SponsorGenprex, Inc.

Started2024-05-09

View on ClinicalTrials.gov ↗

This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).

Amendment history 2 changes detected by DataLookout

2026-09-12

Primary completion pushed: 2026-06 → 2027-12

2026-09-12

Completion pushed: 2027-08 → 2028-06

Trial Details

NCT Number	NCT05703971
Lead Sponsor	Genprex, Inc.
Conditions	Small Cell Lung Cancer Extensive Stage
Enrollment	62 participants
Start Date	2024-05-09
Primary Completion	2027-12 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-09-11